Outcomes of Alcohol Septal Ablation in Younger Patients With
Obstructive Hypertrophic Cardiomyopathy

J 2017

Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy

LIEBREGTS, Max, Lothar FABER, Morten K. JENSEN, Pieter A. VRIESENDORP, Jaroslav JANUSKA et. al.

Základní údaje

Originální název

Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy

Autoři

LIEBREGTS, Max (528 Nizozemské království), Lothar FABER (276 Německo), Morten K. JENSEN (208 Dánsko), Pieter A. VRIESENDORP (528 Nizozemské království), Jaroslav JANUSKA (203 Česká republika), Jan KREJČÍ (203 Česká republika, garant, domácí), Peter R. HANSEN (208 Dánsko), Hubert SEGGEWISS (276 Německo), Dieter HORSTKOTTE (276 Německo), Radka ADLOVA (203 Česká republika), Henning BUNDGAARD (208 Dánsko), Jurriën M. ten BERG (528 Nizozemské království) a Josef VESELKA (203 Česká republika)

Vydání

JACC - Cardiovascular Interventions, New York, Elsevier Science Inc. 2017, 1936-8798

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 9.881

Kód RIV

RIV/00216224:14110/17:00097296

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.jcin.2017.03.030

UT WoS

000402974900013

Klíčová slova anglicky

alcohol septal ablation; hypertrophic cardiomyopathy; septal reduction therapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 16:15, Soňa Böhmová

Anotace

V originále

OBJECTIVES The aim of this study was to describe the safety and outcomes of alcohol septal ablation (ASA) in younger patients with obstructive hypertrophic cardiomyopathy. BACKGROUND The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for older patients and patients with serious comorbidities. Data on long-term age-specific outcomes after ASA are scarce. METHODS A total of 1,197 patients (mean age 58 +/- 14 years) underwent ASA for obstructive hypertrophic cardiomyopathy. Patients were divided into young (<= 50 years), middle-age (51 to 64 years), and older (>= 65 years) groups. RESULTS Thirty-day mortality and pacemaker implantation rates were lower in young compared with older patients (0.3% vs. 2%[p = 0.03] and 8% vs. 16%[p < 0.001], respectively). Ninety-five percent of young patients were in New York Heart Association functional class I or II at last follow-up. During a mean follow-up period of 5.4 +/- 4.2 years, 165 patients (14%) died. Annual mortality rates of young, middle-age, and older patients were 1%, 2%, and 5%, respectively (p < 0.01). Annual adverse arrhythmic event rates were similar in the 3 age groups at about 1%(p = 0.90). Independent predictors of mortality in young patients were age, female sex, and residual left ventricular outflow tract gradient. Additionally, young patients treated with >= 2.5 ml alcohol had a higher all-cause mortality rate (0.6% vs. 1.4% per year in patients treated with < 2.5 ml, p = 0.03). CONCLUSIONS ASA in younger patients with obstructive hypertrophic cardiomyopathy was safe and effective for relief of symptoms at long-term follow-up. The authors propose that the indication for ASA can be broadened to younger patients. (J Am Coll Cardiol Intv 2017;10:1134-43) (C) 2017 by the American College of Cardiology Foundation.

Citovat

LIEBREGTS, Max, Lothar FABER, Morten K. JENSEN, Pieter A. VRIESENDORP, Jaroslav JANUSKA, Jan KREJČÍ, Peter R. HANSEN, Hubert SEGGEWISS, Dieter HORSTKOTTE, Radka ADLOVA, Henning BUNDGAARD, Jurriën M. ten BERG a Josef VESELKA. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC - Cardiovascular Interventions. New York: Elsevier Science Inc., 2017, roč. 10, č. 11, s. 1135-1143. ISSN 1936-8798. Dostupné z: https://dx.doi.org/10.1016/j.jcin.2017.03.030.

@article{1386644,
   author = {Liebregts, Max and Faber, Lothar and Jensen, Morten K. and Vriesendorp, Pieter A. and Januska, Jaroslav and Krejčí, Jan and Hansen, Peter R. and Seggewiss, Hubert and Horstkotte, Dieter and Adlova, Radka and Bundgaard, Henning and Berg, Jurriën M. ten and Veselka, Josef},
   article_location = {New York},
   article_number = {11},
   doi = {http://dx.doi.org/10.1016/j.jcin.2017.03.030},
   keywords = {alcohol septal ablation; hypertrophic cardiomyopathy; septal reduction therapy},
   language = {eng},
   issn = {1936-8798},
   journal = {JACC - Cardiovascular Interventions},
   title = {Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy},
   volume = {10},
   year = {2017}
}

TY  - JOUR
ID  - 1386644
AU  - Liebregts, Max - Faber, Lothar - Jensen, Morten K. - Vriesendorp, Pieter A. - Januska, Jaroslav - Krejčí, Jan - Hansen, Peter R. - Seggewiss, Hubert - Horstkotte, Dieter - Adlova, Radka - Bundgaard, Henning - Berg, Jurriën M. ten - Veselka, Josef
PY  - 2017
TI  - Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy
JF  - JACC - Cardiovascular Interventions
VL  - 10
IS  - 11
SP  - 1135-1143
EP  - 1135-1143
PB  - Elsevier Science Inc.
SN  - 19368798
KW  - alcohol septal ablation
KW  - hypertrophic cardiomyopathy
KW  - septal reduction therapy
N2  - OBJECTIVES The aim of this study was to describe the safety and outcomes of alcohol septal ablation (ASA) in younger patients with obstructive hypertrophic cardiomyopathy. BACKGROUND The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for older patients and patients with serious comorbidities. Data on long-term age-specific outcomes after ASA are scarce. METHODS A total of 1,197 patients (mean age 58 +/- 14 years) underwent ASA for obstructive hypertrophic cardiomyopathy. Patients were divided into young (<= 50 years), middle-age (51 to 64 years), and older (>= 65 years) groups. RESULTS Thirty-day mortality and pacemaker implantation rates were lower in young compared with older patients (0.3% vs. 2%[p = 0.03] and 8% vs. 16%[p < 0.001], respectively). Ninety-five percent of young patients were in New York Heart Association functional class I or II at last follow-up. During a mean follow-up period of 5.4 +/- 4.2 years, 165 patients (14%) died. Annual mortality rates of young, middle-age, and older patients were 1%, 2%, and 5%, respectively (p < 0.01). Annual adverse arrhythmic event rates were similar in the 3 age groups at about 1%(p = 0.90). Independent predictors of mortality in young patients were age, female sex, and residual left ventricular outflow tract gradient. Additionally, young patients treated with >= 2.5 ml alcohol had a higher all-cause mortality rate (0.6% vs. 1.4% per year in patients treated with < 2.5 ml, p = 0.03). CONCLUSIONS ASA in younger patients with obstructive hypertrophic cardiomyopathy was safe and effective for relief of symptoms at long-term follow-up. The authors propose that the indication for ASA can be broadened to younger patients. (J Am Coll Cardiol Intv 2017;10:1134-43) (C) 2017 by the American College of Cardiology Foundation.
ER  -

LIEBREGTS, Max, Lothar FABER, Morten K. JENSEN, Pieter A. VRIESENDORP, Jaroslav JANUSKA, Jan KREJČÍ, Peter R. HANSEN, Hubert SEGGEWISS, Dieter HORSTKOTTE, Radka ADLOVA, Henning BUNDGAARD, Jurri$\backslash$''en M. ten BERG a Josef VESELKA. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. \textit{JACC - Cardiovascular Interventions}. New York: Elsevier Science Inc., 2017, roč.~10, č.~11, s.~1135-1143. ISSN~1936-8798. Dostupné z: https://dx.doi.org/10.1016/j.jcin.2017.03.030.

Podrobný výpis o publikaci